# Biocom Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biocom-co

- Industry: Medical Devices & Equipment
- Headquarters: Seoul, South Korea
- Website: www.biocom.kr/
- Latest round: Series A (Dec 29, 2025)
- Investors on record: 4

## About

Founded in 2022 and based in Seoul, South Korea, Biocom Co., Ltd., operates as a manufacturing company that manufactures diagnostic kits for non-face-to-face testing of gut flora, heavy metals, and food allergies. In December 2025, Biocom Co., Ltd. raised an undisclosed amount of series A funding from new investors NH Bank, NICE Investment Partners, and Shinhan Venture Investment. As of 2025, the company is co-led by its CEOs, Tae-jun Jeon and Hee-young Jung.

The company offers comprehensive health testing and nutritional solutions, including nutritional heavy metal testing, food intolerance testing, intestinal bacteria testing, health functional foods, and subscription-based supplements.

Biocom offers a variety of tests to assess different aspects of health, including heavy metal levels, food intolerances, and intestinal bacteria.

The company will use the December 2025 funding to bolster its technology for metabolite analysis and broaden its data-based healthcare sector.

## Funding rounds

- Series A, Dec 29, 2025 — NH Bank, Shinhan Venture Investment, NICE Investment Partners
- Seed, Dec 31, 2023 — ENSL Partners
- Seed, Aug 31, 2023 — ENSL Partners

## Investors

- ENSL Partners (https://capitalatlas.ai/funds/ensl-partners) — Seed
- NH Bank — Series A
- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series A
- NICE Investment Partners (https://capitalatlas.ai/funds/nice-investment-partners) — Series A